Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

NCT02867384 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

181

Enrollment

OTHER

Sponsor class

Conditions

Graft vs. Host Disease

Interventions

DRUG: Obinutuzumab
DRUG: Placebo

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]